efavirenz


Also found in: Medical, Acronyms, Wikipedia.

e·fa·vir·enz

 (ə-fä′vîr-ĕnz′)
n.
An antiviral drug, C14H9ClF3NO2, that is a non-nucleoside reverse transcriptase inhibitor and is used in combination with other drugs for the treatment of HIV infection.

[e(thyne) + f(luoro)- + -virenz, antiretroviral drug suffix (vir(us) + (b)enz(yl)).]
Translations

efavirenz

n efavirenz m
References in periodicals archive ?
Speaking during the launch of the sixth National Antiretroviral Therapy (ART) guidelines here on Thursday Senior Medical Advisor for HIV and TB, Dr Ndapewa Hamunime explained that the new drug is replacing one medicine known as Efavirenz in the current regiment of first-line HIV patients' treatment-meaning newly HIV diagnosed patients.
class="font-size--16 MsoNormalThose of childbearing age between 15 and 49 years who were on the drug, were to be given Efavirenz as the first-line treatment.
Generic versions of efavirenz, a component of Atripla, are available in the United States, Canada and Europe.
MONDAY, June 25, 2018 (HealthDay News) -- For persons living with HIV (PLHIV) in Uganda, use of efavirenz is not associated with increased risk of depression or suicidal ideation, according to a study published online June 26 in the Annals of Internal Medicine.
The current preferred first-line regimen is a fixed-dose combination tablet comprising three antiretroviral agents, including efavirenz (EFV).
The United States Food and Drug Administration (FDA) approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and paediatric patients weighing at least 40 kg.
Pharmaceutical company Mylan NV (NASDAQ:MYL) stated on Wednesday that it will introduce its third cost-saving US Food and Drug Administration (FDA) approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) in 600 mg/300 mg/300 mg tablets in the US for the treatment of HIV.
The two most commonly used NNRTIs Nevirapine and Efavirenz are frequently used as part of the triple combination first-line ART regimen [5].
[9] The World Health Organization (WHO, 2010 revision) guidelines recommend initiation of antiretroviral therapy with two NRTI (zidovudine or tenofovir disoproxil fumarate with lamivudine [3TC] or emtricitabine [FTC) and a NNRTI (efavirenz [EFV] or nevirapine).
ART regimen combining lamivudine, Efavirenz, and Nevirapine was received by 48.8% (20/41) of patients.
Therefore, ZDV/3TC/NVP (zidovudine plus lamivudine plus nevirapine) or EFV (efavirenz) and TDF/3TC (FTC)/EFV (tenofovir plus lamivudine or emtricitabine plus efavirenz or NVP (nevirapine)) are continued to be the most important components of ART regimens in resource constrained settings [1].